

REFERENCES

- Abdelrazik N and Ghanem H (2007):*** Failure of puberty in Egyptian beta thalassemic patients: experience in north east region - Dakahlia province. Hematology. 2007 Oct;12(5):449-56
- Adamkiewicz, T.V.; Berkovitch, M.; Krishnan, C.; Polsinelli, C.; et al. (1998):*** Infection due to Yersinia enterocolitic in a series of patients with beta-thalassemia: incidence and predisposing factors. Clin. Infect. Dis., 27(6): 136-6.
- Aessopos, A.; Farmkis, D. and Karagiorga, M. (2001):*** Cardiac involvement in thalassemia intermedia a multicenter study. Blood, 97: 3411-3418.
- Agarwal MB, Shah S, Vishwanathan C, Rajadhyaksha G, et al. (1992):*** Thyroid dysfunction in multi-transfused iron loaded thalassemia patients. Indian Pediatr;. 1992 Aug;29(8):997-102.
- Ailhaud G, Grimaldi P, and Negrel R (1992):*** Cellular and molecular aspects of adipose tissue development. Annu Rev Nutr ; 12: 207-233.
- Alan R. Cohen, Renzo Galanello, Dudley J. Pennell,et al (2004)*** Thalassemia. Hematology issue1;14-34.
- Aldudak, B.; Karabay Bayazit, A.; Noyan, A.; Ozel, A.; et al.(2000):*** Renal function in pediatric patients with beta-thalassemia major. Pediatr. Nephrol., 15(1-2): 109-112.

- Aliberti, B.; Patrikiou, A.; Terentiou, A.; Frangatou, et al. (2001):** Spinal cord compression due to extramedullary hematopoiesis in patients with thalassemia *Journal of Neurology*, 248(1): 18-22.
- Allain TJ and McGregor AM (1993):** Thyroid hormones and bone. *J Endocrinol* ; 139: 9-18.
- Alter, B.P. (2003):** Orkin SH, Nathan DG. The Thalassemias. In: Nathan and Oski's Hematology of Infancy and Childhood, 6th ed, Nathan, DG, Orkin, SH, Ginsberg, D, Look, AT (Eds), WB Saunders, Philadelphia 2003. p. 842.
- Anderson LJ. (2002)** Assessment of cardiac iron overload in thalassaemia. MD Thesis. Imperial College, London. p. 842.
- Anderson L, Bunce N, and Davis B. (2001)** Reversal of siderotic cardiomyopathy: a prospective study with cardiac magnetic resonance (CMR). *Heart*; 85(suppl 1):33.
- Angelopoulos NG, Goula A, Rombopoulos G, Kaltzidou V, et al. (2006):** Hypoparathyroidism in transfusion-dependent patients with beta-thalassemia. *J Bone Miner Metab*; 24:138–145.
- Angelucci E, Bai H and Centis F. (2002)** Enhanced macrophagic attack on β -thalassemia major erythroid precursors. *Haematologica*; 87:578-583.
- Angelucci E, Muretto P, Nicolucci A. et al., (2002)** Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. *Blood*; 100:17–21.

- Araujo A, Kosaryon M and MacDowell A. (1996)** A novel delivery system for continuous desferrioxamine infusion in transfusional iron overload. *Br J Haematol*; 93:835–837.
- Asakuran Y, Tachibana K, Deniz Yilmaz, et al., (2002)** Hypothalamo-pituitary hypothyroidism detected by neonatal screening for congenital hypothyroidism using measurements of thyroid-stimulating hormone and thyroxine. *Acta Pediatr*; 91:172–177.
- Atichartakan V., Likittanasombat K., Chuncharunee S.Chandanamattha P., et al. (2003):** Pulmonary arterial hypertension in previously splenectomized patients with beta thalassemic disorders. *Int J. Hematol.*; 78(2):139-145.
- Aydinok Y, Serpil Erermis, Nagihan Bukusoglu, Deniz Yilmaz , et al. (2005)** Psychosocial implications of Thalassemia Major. *Pediatrics International*. Volume 47 Issue 1, Page 84 -92
- Aydinok Y,Sukran Darakan,Aziz Polat,Kaan Kavakli , et al. (2002)** Endocrine coplications in patients with β -Thalassemia Major.*Journal of Tropical pediatrics* Vol.48:50 – 54.
- Barragan E., Bolufer P, and Prieto F., (2006):** Molecular detection of Spanish delta beta thalassemia during prenatal diagnosis. *Clin Chim Acta*; 368: 195-8.
- Barton JC. (2007):** Drug evaluation: Deferritin for iron overload disorders. *J Drug*; 10(7):480-90.
- Becker DV, Bigos ST, Gaitan E, Morris JC, Rallison ML, Spencer CA, et al. (1993):** Optimal use of blood tests for assessment of thyroid function. *JAMA*; 269 (21):2736.

- Beck-Peccoz P. and Persani L. (1994):** Variable biological activity of thyroid-stimulating hormone. *Eur J Endocrinol*; 131:331.
- Berkovitch M, Bistritzer T and Milone SD., (2000):** Iron deposition in the anterior pituitary in homozygous β -thalassemia: MRI evaluation and correlation with gonadal function. *J Pediatr Endocrinol Metab*; 13: 179-184.
- Bernal J (1999):** Iodine and brain development. *Biofactors* ;10: 271-276.
- Beutler E, Hoffbrand AV and Cook JD. (2003):** Iron deficiency and overload. *Hematology Am Soc Hematol Educ Program.*:46–52.
- Bonetti, M.G.; Cashivta, Scanderbery, A.; Criconia, et al. (1999):** Hepatic iron overload in thalassemic patients: proposal and validation of an MRI method of assessment. *Pediatric Radiol.*, 26(9): 650-6.
- Borgna-Pignatti Cand Cohen A. (2003)** Evaluation of a new method of administration of the iron chelating agent deferoxamine. *J Pediatr.*; 130:86–88.
- Borgna-Pignatti C, Rugolotto S and De Stefano P. (2004)** Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. *Haematologica*; 89:1187-1193.
- Bosma PJ, (2000)** The genetic basis of the reduced expression of bilirubin UCP-glucuronosul transferase 1 in Gilbert's syndrome. *N Engl J Med*; 333:1171-5.)

- Breuer J. (1996)** Report on the symposium "drug effects in clinical chemistry" European Journal of Clinical Biochemistry; 34:385-386.
- Breuer W, Ronson A and Slotki I. (2000)** The assessment of serum non-transferrin-bound iron in chelation therapy and iron supplementation. Blood; 95:2975–2982.
- Camargo, J. L., & Gross, J. L. (2004):** Glycohemoglobin (GHb): Clinical and analytical aspects. Arquivos Brasileiros de Endocrinologia e Metabologia; 48, 451-463.
- Cantineaux, B.; Hariga, C.; Ferster, A.; De Maertelaere, et al. (1997):** Neutrophil dysfunctions in thalassemia major : The role of cell iron overload. Eur. J. Haematol., 67(4): 238-44.
- Capellini M, (2000)** eds.Guidelines for Clinical Management of Thalassemia. Nicosia, Cyprus: Thalassemia International Federation; ; 48, 451-463.
- Cario H, Holl RW, Debatin KM and Kohne E. (2003):** Insulin sensitivity and beta-cell secretion in thalassaemia major with secondary hemochromatosis: assessment by oral glucose tolerance test. Eur J Pediatr; 162: 139-146.
- Cavallo L, Mautone A, Altomare M, Licciulli M, et al. (1981):** Pituitary-thyroid function in Children. with beta-thalassaemia major. Acta Endocrinal (Copenh).; 1981 Jan;96(1):59-64. No abstract available.
- Cazzola M., Bornga Pignattic and Locatelli F., (2002):** A moderate transfusion regimen may reduce iron loading in β thalassemia

major without producing excessive expansion of erythropoiesis. Transfusion; 37:135-40.

Centis F, Lucarelli G, Altomare M, et al., (2000) The importance of erythroid expansion in determining the extent of apoptosis in erythroid precursors in patients with β -thalassemia major. Blood; 96:3624-3629.

Chang, Y.C.; Smith, K.D.; Moore, R.D.; Sergeant, G.R. , et al. (1995): An analysis of fetal hemoglobin variation in sickle cell disease : the relative contribution of the X-linked factor, beta-globin haplotypes, alpha- globin gene number gender and age. Blood, 85(4): 1111-1117.

Chern JP, Lin KH, Lu MY, Lin DT, et al. (2001): Abnormal glucose tolerance in transfusion-dependent beta-thalassemic patients. Diabetes Care; 24: 850-854.

Clarke, G.M. and Higgins, T.N. (2000): Laboratory investigation of hemoglobinopathies and thalassemias: review and update. Clin. Chem., 46: 1284-90.

Cohen AR, (2004) Thalassemia. Hematology (Am Soc Hematol Educ Program) ;1:14-34.

Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR. et al., (2004) Complications of β -thalassemia major in North America. Blood;104:34-39.

Darling DS, Carter RL, Yen PM, Welborn JM, et al. (1993): Different dimerization activities of a and b thyroid hormone receptor isoforms. J Biol Chem; 268: 10221-10227.

- Davis BA, Porter JB. (2000)** Long-term outcome, of continuous 24-hour deferoxamine infusions via indwelling intravenous catheters in high-risk beta-thalassemia. *Blood.*; 95:1229–1236.
- De Groot LJ. (1999)** Dangerous dogmas in medicine: the nonthyroidal illness syndrome. *J Clin Endocrinol Metab*; 84:151–164.
- De Sanctis V, De Sanctis E, Ricchieri P, Gubellini E, et al. (2008):** *Pediatr Endocrinal Rev*- 2008 oct, 6 suppl 1: 174 - 80
- De Sanctis V, Eleftheriou A and Malaventura C, (2004):** On behalf of Thalassemia International Federation. Study group on growth and endocrine complications in thalassemia. Prevalence of endocrine complications and short stature in patients with thalassemia major: A Multicentre study by the Thalassemia International Federation (TIF). *Ped Endocrinol Rev*; 2(2):248-255.
- De Sanctis V, Printor C, Vullo C, Hoffbrand VA, et al. (1995):** Multicentre study on endocrine complications in thalassemia major. *Clin Endocrinol*; 42:581-6.
- De Sanctis V and Urso L. (1999):** Clinical experience with growth hormone treatment in patients with thalassemia major. *BioDrug*; 11:79-85.
- De Sanctis V and Wonke B. (1998):** Growth and endocrine complication in thalassemia. Roma: Mediprint; p. 17-30.
- De Sanctis V. (2002):** Growth and puberty and its management in thalassemia. *Horm Res*; 58 (suppl 1):72-9.

- Delanghe JD. (2003)** "HIV infection and iron over load" *AIDS*; 12:1027.
- Dillmann WH (1990):** Biochemical basis of thyroid hormone action in the heart. *Am J Med*; 88: 626-630.
- Dillmann WH (1996):** Thyroid hormone action and cardiac contractility a complex affair. *Endocrinol*; 137: 799-801.
- Di Naro E, Ghezzi F, Vitucci A, et al., (2000)** Prenatal diagnosis of β -thalassemia using fetal erythroblasts enriched from maternal blood by a novel gradient. *Mol Hum Reprod*; 6:571-574.
- Dmochowski K, Finegood DT, Francombe W, Zinman B., et al. (1993):** Factors determining glucose tolerance in patients with thalassemia major. *J Clin Endocrinol Metab*; 77: 478-483.
- Ehlers, K.H.; Giardina, P.J. and Lesser, M.L. (1999):** Prolonged survival in patient with beta thalassemia major treated with desferrioxamine. *J. Pediatric*; 118:54-545.
- Ekins RP (1998):** The science of free hormone measurement. *Proc uk nequas Meeting*; 3:35-59.
- El-Beshlawy A, El Accaoui R, Abd El-Sattar M. et al., (2007)** Effect of L-carnitine on the physical fitness of thalassemic patients. Ann Hematol. Jan; 86(1):31-4.
- El-Beshlawy A, Ilham Youssry, Ragab, et al., (2007)** Skin Iron Concentration: a Simple, Highly Sensitive Method for Iron Stores Evaluation in Thalassemia Patients. Hemoglobin, Volume 31, Issue 3: 357 – 365

El-Beshlawy, A.; Kaddah, N.; Ragab, L.; Hussein, L. , et al. (1999):
Thalassemic prevalence and status in Egypt. *Pediatr. Res.*,
45(5): 102-7.

El-Beshlawy A, Seoud H, Ibrahim A, et al., (2005) Apoptosis in
thalassemia major reduced by a butyrate derivative. *Acta*
Haematol; 114(3):155-159.

Eldor A and Rachmilewitz EA. (2002) The hypercoagulable state in
thalassemia. *Blood*; 99:36-43.

Elliott P. Vichinsky. (2005) Changing Patterns of Thalassemia
Worldwide. *Annals of the New York Academy of Sciences*,
Volume 1054 Page 18

Fibach E. (2001) Cell culture and animal models to screen for
promising fetal hemoglobin-stimulating compounds. *Semin*
Hematol; 38:374-381.

Filosa A, Di Maio S, Nielsen P, et al, (2006) Longitudinal study on
thyroid function in patients with thalassemia major. *J. Pediatr*
Endocrinol Metab. Dec; 19(12):1397-404.

Fischer R, Longo F, Nielsen P, et al., (2003) Monitoring long-term
efficacy of iron chelation therapy by deferiprone and
desferrioxamine in patients with β -thalassaemia major:
application of SQUID biomagnetic liver susceptometry. *Br J*
Haematol; 121:938–948.

Fisher DA. (1996) Disorders of the thyroid in the newborn and
infant. In: Sperling MA, ed. *Pediatric*
endocrinology. Philadelphia: Saunders;:5170.

- Forget BG. (2001)** Molecular Genetics of the Human Globin Genes. In: Steinberg MH, Forget BG, Higgs DR, Nagel RL, editors. Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Managmnt. Cambridge, UK: Cambridge University Press; p.117-30.
- Fucharoen M and Winichagoon P. (2000):** Clinical and hematologic aspects of hemoglobin E beta-thalassemia. Curr opin Hemat; 7:106-112.
- Gabutti Vand Piga A. (1996)** Results of long-term iron chelating therapy. Acta Haematol; 95:26–36.
- Galanello R, Piras S,, Kattamis A, et al., (2001)** Cholelithiasis and Gilbert's syndrome, in homozygous β -thalassaemia. Br J Haematol; 115:926-8.
- Ganz T. (2003)** Heparidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood;102:783-788.
- Gillam MPand Kopp P. (2001)** Genetic defects in thyroid hormone synthesis.Curr Opin Pediatr; 13:354–372.
- Goussetis E, Perisreri J, Kitra V, Kattamis A, et al. (2000):** Combined umbilical cord blood and bone marrow transplantation in the treatment of beta thalassemia major. Pediatr. Hematol Oncol; 17 (4): 307-14.
- Grundy RG, Woods KA, Savage MO and Evans JP.(1994):** Relationship of endocrinopathy to iron chelation status in young.patients with thalassaemia major . Arch Dis Child; 1994 Aug;71(2):128-32.

- Guadano-Ferraz A, Obregon MJ, St Germain DL, and Bernal J. (1997):** The type 2 iodothyronine deiodinase is expressed primarily in glial cells in the neonatal rat brain. *Proc Natl Acad Sci USA*; 94: 10391-10396.
- Gulati R, Bhatia Vand Agarwal SS.(2000):** Early onset of endocrine abnormalities in beta - thalassemia major in a developing country. *J Pediatric Endocrinol Metab*; 2000 Jun;13(6):651-6.
- Hardison R. (2001)** Organization, Evolution, and Regulation of the Globin Genes. In: Steinberg MH, Forget BG, Higgs DR, Nagel RL, eds. *Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management*. Cambridge,UK: Cambridge University Press; p.95-116.
- Haverfield EV, , (2004):** UGT1A1 variation and gallstone formation in sickle cell disease. *Blood* ; (Online Paper).
- Hayward A, Ambruso D, Battaglia F, Donlon T, et al. (1998):** Microchimerism and tolerance following intrauterine transplantation and transfusion for alpha-thalassemia-1. *Fetal Diagn Ther*; 13:8-14.
- Higgs DR, Thein SL and Wood WG. (2001)** The pathophysiology of the thalassaemias. In: Weatherall DJ, Clegg B, eds. *The thalassaemia syndromes*. 4th ed. Oxford, England: Blackwell Science: 192-236.
- Hoffbrand AV, Cohen A and Hershko C. (2003)** Role of deferiprone in chelation therapy for transfusional iron overload. *Blood*; 102:17–24

- Honig GR (2000):** Hemoglobin disorders in: Nelson textbook of pediatrics. Behrman RE, kliegman RM and Jenson HB (eds). Sixteenth edition WB Saunders Company. Philadelphia, London Toronto, Montereal Sydney, Tokyo;, p 1478.
- Ikuta T, Atweh G, Boosalis V, White GL, et al. (1998)** Cellular and molecular effects of a pulse butyrate regimen and new inducers of globin gene expression and hematopoiesis. Ann N Y Acad Sci; 6(30):850:87-99.
- Issaragrisil, S. (2002):** Stem cell transplantation for thalassemia Int. J. Hematol.; 1 (76 Supply):307-9.
- Jain M, Sinha RS, Chellani H and Anand NK.(1995):**Assessment of thyroid functions and its role in body growth in thalassemia major. Indian Pediatr; 1995 Feb;32(2):213-9.
- Jaruratanasirikul S, Wongcharnchailert M,Laosombat V, Sangsupavanich P, et al. (2007) :**Thyroid function in beta-thalassemic children receiving. hypertransfusions with suboptimal iron-chelating therapy J Med Assoc Thai; 2007 Sep;90(9):1798-802.
- Jensen CE, Tuck SM, Boosalis V, et al (1997)** Incidence of endocrine complications and clinical disease severity related to genotype analysis and iron overload in patients with beta-thalassaemia. Eur J Haematol. 59(2):76-81.
- Jensen P D, Jensen FT, Christensen T, et al., (2003)** Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close

relation between myocardial iron content and chelatable iron pool. *Blood*; 101: 4632–4639.

Karnon J, Zeuner D, Brown J, Ades AE, et al. (1999) Lifetime treatment costs of β -thalassaemia major. *Clin Lab Haematol*; 21:377-385.

Kattamis A, Kassou C, Ladis V, et al., (2002) Safety and efficacy of combining deferiprone and deferoxamine in iron chelation therapy in patients with thalassemia . *Blood*; 100:11.

Kearney SL, Nemeth E, Neufeld EJ, Thapa D, et al. (2007): Urinary hipcidin in congenital chronic anemias. *Pediatr Blood Cancer*; 48:57-63.

Kenneth A. Woeber, (1999) The Year in Review: The Thyroid, *Ann Intern Med*.;131:959-962.

Khalifa A.S; Sallam T and Tawfeek Z; (1990): Effect of splenectomy on platetel function in β -thalassemia. *Egypt J. Pediatr*.; 7(1-2): 201.

Khalifa AS, el-Hashemite N, Heshmat NM, Delhanty JD, et al. (1997) Identification of novel Asian Indian and Japanese mutations causing beta-thalassaemia in the Egyptian population. *Hum Genet*. Feb; 99(2):271-4.

Khalifa AS, Salem M, Mounir E, El-Tawil MM, et al. (2004): Abnormal glucose tolerance in Egyptian beta thalassemic patients: Possible association with genotyping. *Pediatr Diabetes*; 5: 126-132.

- Khong PL, Chan GC, Au WY, Fong DY, et al. (2003):** Thin section CT features and correlation with pulmonary function and iron overload in beta-thalassemia. *Radiology*; 229(2):507-512.
- Kinlaw WB, Church JL, Harmon J, and Mariash CN (1995):** Direct evidence for a role of the "spot 14" protein in the regulation of lipid synthesis. *J Biol Chem*; 270: 16615-16618.
- Klein I, and Ojamaa K. (1998):** Thyrotoxicosis and the heart. *Endocrinol Metab Clin N Am*; 27: 51-62.
- Kleini I and Ojamaa K. (2001)** Thyroid hormone and the cardiovascular system. *N Engl J Med*; 344:501–509.
- Koch CA and Sarlis NJ. (2001)** The spectrum of thyroid disease in childhood and its evolution during transition to adulthood: natural history, diagnosis, differential diagnosis and management. *J Endocrinol Invest*; 24:659–675.
- Koibuchi N, and Chin W (2000):** Aberrant postnatal cerebellar development in transgenic mouse expressing a dominant negative thyrid hormone receptor. In: *Proc Annu Meet Endocr Soc* 81d Toronto Canada; p. 374.
- Ko L, Cardona GR, and Chin WW (2000):** Thyroid hormone receptor-binding protein, an LXXLL motif-containing protein, functions as a general coactivator. *Proc Natl Acad Sci USA* ;97: 6212-6217.
- Kong Y, Zhou S, Kihm AJ, et al., (2004)** Loss of alpha-hemoglobin-stabilizing protein impairs erythropoiesis and exacerbates β -thalassemia. *J Clin Invest*; 114:1457-1466

- Kuypers FA and de Jong K. (2004)** the role of phosphatidylserine in recognition and removal of erythrocytes. *Cell Mol Biol*; 50:147-158.
- Kwiatkowski JL (2008):** Oral iron chelator. *Pediatr Clin N Am*; 55: 461-482.
- Ladenson PW (1996):** Optimal laboratory testing for diagnosis and monitoring of thyroid nodules, goiter and thyroid cancer. *Clin Chem*; 1996; 42:1,183-187.
- Landau H, Matzoth I, Landau-Cordova Z, Goldfarb A, et al.(1993):** Cross-sectional and longitudinal study of the pituitary-thyroid axis in patients with. thalassaemia major *Clin Endocrinol (Oxf)*; 1993 Jan;38(1):55 – 61.
- Leger J, Marinovic D, Garel C, Bonaiti-Pellie C, et al. (2002)** Thyroid development anomalies in first degree relatives of children with congenital hypothyroidism.*J Clin Endocrinol Metab* 87:575–580.
- Li CK; Chik, K.W.; Lam, C.W.K.; To, K.F .; et al. (2002):** Liver disease in transfusion dependent thalassemia major. *Arch. Dis. Child*, 86:344-347.
- Liu DY, Liu ZD and Hider RC. (2002)** Oral iron chelators development and application. *Clin Haematol.*; 15:369–384.
- Louthrenoo, O.; Siltipreechacharn, S; Thanrattanakor, P. and Sanguansermisri, T. (2004):** Psychological problems in children with B thalassemia. *Med Assoc Thai.*, 85(8): 881-5.

- Low LCK. (2001):** Growth and endocrine function in beta-thalassaemia major. In Desai MP, Bhatia V, Men on PSN, eds. Pediatric Endocrine Disorders, India. Orient Longman, India; 411-415.
- Low LCK. (2005):** Growth of children with β thalassemia major: Indian J. Pediatr; 72(2):159-164.
- Lukens, T.N. (2000):** The thalassemia and related disorders. In: Wintrobe's clinical hematology. 9th edition. Lee GR.; Bithell TC; Foerster J; Athens JW; Lukens J.N. (eds). Lea and Febiger; Philadilphia PA; 1:1102-45.
- Lung HY, Meeus IS, Weinberg RS and Atweh GF. (2000)**In vivo silencing of the human gamma-globin gene in murine erythroid cells following retroviral transduction. Blood Cells Mol Dis; 26:613-619.
- Magro S, Puzzonia P, Porcu L, et al., (1990)** hypothyroidism in patients with thalassemia syndromes. Acta Haematol;84(2):72-6.
- Mansberger AR Jr and Wei JP (1993):** Surgical embryology and anatomy of the thyroid and parathyroid glands. Surg Clin North Am Aug; 73(4): 727-46.
- Marini MG, Asunis I, Porcu L, Salgo MG, Loi MG, Brucchiatti A, et al., (2004)** the distal β -globin CACCC box is required for maximal stimulation of the β -globin gene by EKLF. Br J Haematol; 127:114-7.
- Masala A, Meloni T, Gallisai D, Alagna S, Rovasio PP,et al. (1984):** Endocrine functioning in . multitransfused prepubertal patients

with homozygous beta- thalassemia. J Clin Endocrinol Metab;1984 Apr;58(4):667-70.

Mc Donagh KT and Neinhuis AW (1997): The thalassemias. In: Hematology of infancy and childhood. 4th ed., Nathan DG and Oski FA (eds) WB Saunders Company, Philadelphia; P. 783.

Modell B, Khan M and Darlison M. (2000) Survival in beta thalassaemia major in the United Kingdom: data from the U.K. Thalassaemia Register. Lancet; 355:2051–2052.

Mojtahedzadeh F, Kosaryan M, Mahdavi MR, Akbari J., et al.,(2006) The effect of folic acid supplementation in beta-thalassemia major: a randomized placebo-controlled clinical trial. Arch Iran Med. Jul;9(3):266-8.

Monge L, Pinach S, Caramellino L, Bertero MT, Dall'Omo A, et al. (2001): The possible role of autoimmunity in the pathogenesis of diabetes in beta-thalassemia major. Diabetes Metab; 27(2):149-154.

Mosekilde L, Eriksen EF, and Charles P (1990): Effects of thyroid hormones on bone and mineral metabolism. Endocrinol Metab Clin N Am; 19: 35-63.

Najafipour F, Bahrami A, Stazi MA, et al., (2008) a cross-sectional study of metabolic and endocrine complications in beta-thalassemia major. Ann Saudi Med. Sep-Oct; 28(5):361-6.

Nathan, D.G. and Orkin, S.H. (1998) : Hematology of infancy and childhood the thalassemia. W.B. Saunders Company. 85 – 87.

- Nicoloff JT and Spencer CA (1990):** The use and misuse of sensitive thyrotropin assays. *J Clin Endoc Metab*; 71:553-558.
- Olivieri A, Stazi MA, Mastroiacovo P.et al.,(2002)** A population-based study on the frequency of additional congenital malformations in infants with congenital hypothyroidism: data from the Italian registry for congenital hypothyroidism (1991–1998). *J Clin Endocrinol Metab*; 87: 557–562.
- Olivieri NF, and Brittenham GM (1997):** Iron chelating therapy and the treatment of thalassemia. *Blood*; 1997; 1; 89(3):739-761.
- Olivieri NF, Brittenham GM, Matsui D, et al.,(1995)** Iron-chelation therapy with oral deferiprone in patients with thalassemia major. *N Engl J Med*; 332:918–922.
- Olivieri NF. (1999)** The β -thalassemias. *N Engl J Med*; 341:99-109. [Erratum, *N Engl J Med*; 341:1407.
- Olivieri, N.F. and Weatherall, D.J. (2001) :** Thalassemias in pediatric hematology textbook 2nd ed . London, Edinburgh, New York, Philadelphia, Sydney Toronto., 307-327.
- Oppenheimer JH, Schwartz HL, Mariash CN, Kinlaw WB,et al. (1997):** Advances in our understanding of thyroid hormone action at the cellular level. *Endocr Rev* ;8: 288-308.
- Osborne DA. (2002)** Thyroid hormones for preventing neurodevelopmental impairment in preterm infants (Cochrane Review). In:The Cochrane Library, Issue 1. Oxford: Update Software,.

- Pace BS, Shartava A, Pack-Mabien A, Mulekar M, et al. (2003)** Effects of N-acetylcysteine on dense cell formation in sickle cell disease. *Am J Hematol*;73:26-32.
- Pallister, C. and Rotstein, O.D. (2001):** *Yersinia enterocolitica* as a cause of intra-abdominal abscess: the role of iron. *Can. J. Surg.*, 44(22): 135-6.
- Pantelakis S. (1994):**Thyroid disorders and diabetes mellitus as complications of thalassaemia major. *Acta Paediatr Suppl.*;1994 Dec;406:111-3. Review No abstract available.
- Papanikolaou G, Tzilianos M, Christakis JI, et al.,(2005)** Heparin in iron overload disorders. *Blood*;105:4103-4105.
- Peter, L.; Greenberg, Victor Gordeuk, Surapol Issaragrisil, Noppadol Siritanaratkul,et al. (2001):** Major hematologic diseases in the developing world : New Aspects of diagnosis and management of thalassemia , Malarial Anemia and acute leukemia . *Hematology*, (5): 97-105.
- Pfannenstiel P and Saller B (1995):** Schilddrüsenerkrankungen Diagnose and Therapie. *Berliner Medizinische verlaganstalt GmbH*; 2:43-54.
- Piga A, Caglioti C, Fogliacco E and Tricta F.(2003)** Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. *Haematologica*; 88:489–496
- Pootrakul P, Sirankapracha P, Hemsorach S, et al.,(2000)** A correlation of erythrokinetics, ineffective erythropoiesis, and

erythroid precursor apoptosis in Thai patients with thalassemia. *Blood*;96:2606-2612.

Porter J.B.; Jaswon, M.S.; Huehns, E.R.; East, C.A. , et al. (1999): Current strategies and perspectives in thalassemia treatment.. *Br J Haematol* 73(3): 403-9.

Porter JB. (2001) Practical management of iron overload. *Br J Haematol*; 115: 239 -52.

Rachmilewitz EA, Aker M, Perry D and Dover G.(1995) Sustained increase in haemoglobin and RBC following long-term administration of recombinant human erythropoietin to patients with homozygous β -thalassaemia. *Br J Haematol* ;90: 341-345.

Rachmilewitz EA and Schrier S. (2001) The pathophysiology of β -thalassemia. In: Steinberg MH, Forget BG, Higgs DR, Nagel RL, eds. *Disorders of hemoglobin: genetics, pathophysiology, and clinical management*. Cambridge, England: Cambridge University Press: 233-51.

Rachmilewitz EA, Weizer-Stern O and Adamsky K. (2005): Iron and oxidative stress in thalassemia: Eighth International Cooley's Anemia Symposium. *Ann N Y Acad Sci*; 1054:1-6.

Rachmilewitz, E.A. and Aker, M. (1998): The role of recombinant human erythropoietin in the treatment of thalassemia. *Ann. N.Y. Acad. Sci.*, 6(30): 850: 120-138.

- Raiola G, Galati MC, De Sanctis V, Caruso Nicoletti M, Pintor C, et al. (2003):** Growth and puberty in thalassemia major. *J Pediatr Endocrinol Metab*; 16 suppl 2: 259-66.
- Robbins J. (1996):** Thyroid hormone transport proteins and the physiology of hormone binding. In: Gray CH, James VHT, eds. *Hormones in Blood*. London: Academic Press; 96-110.
- Ross DS (1994):** Hyperthyroidism, thyroid hormone therapy, and bone. *Thyroid*; 4: 319-326.
- Rund, D. and Rachmilewitz, E. (2000):** New trends in the treatment of β -thalassemia. *Crit Rev Oncol Hematol*; 33:105-118.
- Rund D and Rachmilewitz EA. (2001)** Pathophysiology of α - and β -thalassemia: therapeutic implications. *Semin Hematol*; 38: 343-349.
- Rund D. and Rachmilewitz E. (2005)** β -Thalassemia, *NEJM*; Volume 353: 1135-1146 September 15, 2005, number 11.
- Sack J, Kaisermann I and Eidlitz-Markus T. (1995)** The importance of thyroglobulin levels in monitoring the treatment of congenital hypothyroidism. *Eur J Endocrinol*; 44:23–28.
- Salerno M, Militeri R, Bravaccio C, et al., (2002)** Effect of different starting doses of levothyroxine on growth and intellectual outcome at four years of age in congenital hypothyroidism. *Thyroid*; 12:45–52.
- Schrier SL and Angelucci E. (2005)** new strategies in the treatment of thalassemia. *Annu Rev Med*. 56:157-171

- Shamshirsaz, A. Bekheirnia, M. Savvas C ,et al.,(2003)** Metabolic and endocrinologic complications in beta-thalassemia major: a multicenter study in Tehran. BMC Endocr Disord.; 3(1):4.
- Singer PA, Cooper DS, Levy EG, Ladenson PW, Braverman LE, Daniels G, et al. (1995):** Treatment guidelines for patients with hyperthyroidism and hypothyroidism. JAMA; 273:808-12.
- Singer, S.T.; Wu, V.; Mignacca, R.; Kuyper, F.A. and Morel, P. (2002):** Immunological reactions in beta thalassemia. Blood, 96(10): 3369-3373.
- Skordis N, Michaelidou M, Savvas C, Loannou Y, Rousounides A, et al. (2006):** The impact of genotype on endocrine complications in thalassemia major. Eur J Hematol;77:150-156.
- Spanos T, Karageorga M, Ladis V, Peristeri J, Hatziliami A, et al. (1995):** Red cell alloantibodies in patients with thalassemia. Vox Sang; 58:50-55.
- Sperling MA ,Behrman RE, Klegman RM ,Jenson HB, et al.(2004) :** Nelson textbook of Pediatrics, 16 th ed WB Saunders company; ,2004:1768.
- Srivatsa A, Marwaha R.K and Muralidharan R. Trehan A(2005):**Assessment of adrenal endocrine function in Asian thalassemics. Indian Pediatr; 42:31-35.
- Surks MI, chopra IJ, Mariash CN, Nicoloff JT , et al. (1990):** American Thyroid Association for The Use of Laboratory Tests In Thyroid Disorders. JAMA; 263:1529-1532.

- Suvarna J, Ingle H and Deshmukh CT, (2006):** thalassemia
Insulin resistance and beta cell function in chronically
transfused patients of major :Indian J.Pediatr;43- 34.
- Tavazzi D, Duca L, Graziadei G, Comino A, Fiorelli G, et al.(2001)**
Membrane-bound iron contributes to oxidative damage of β -
thalassemia intermedia erythrocytes. Br J Haematol; 112:48-
50.
- Telfer PT, Prescott E, Holden S, et al., (2000)** Hepatic iron
concentration combined with long-term monitoring of serum
ferritin to predict complications of iron overload in
thalassaemia major. Br J Haematol.;110:971-77.
- Testa U.(2004)** Apoptotic mechanisms in the control of erythropoiesis.
Leukemia; 18:1176-1199.
- Thein SL. (2005)** Structural Variants with a b-thalassemia phenotype.
In: Steinberg MH, Forget BG, Higgs DR, Nagel RL, editors.
Disorders of Hemoglobin: Genetics, Pathophysiology, and
Clinical Management. Cambridge,UK: Cambridge University
Press, Cambridge,UK;. p. 342-55.
- Thuret, I. (2001):** Therapeutic management of patient with thalassemia
major. Bull. Soc. Pathol. Exat., 94(2): 95-7.
- Toumba M, Sergis A, Kanaris C and Skordis N.(2007)** Endocrine
complications in patients with thalassaemia major. Pediatr
Endocrinol Rev. Dec; 5(2):642-8.
- Tovo TA, Minicro R, Barbara C, et al,(1998):** Serum immunoglobins in
homozygous beta-thalassemia. Acta Hematol, 65-21.

- Van de Velde H, Georgiou I, et al., (2004)** Novel universal approach for preimplantation genetic diagnosis of beta-thalassaemia in combination with HLA matching of embryos. *Hum Reprod.*;19:700–708.
- Van Vliet G.(2001)** Treatment of congenital hypothyroidism. *Lancet*; 358:86–87.
- Voskarido, E.; Kyrtsolis, M.C.; Terpos, E.; Skorchili, M. , et al. (2000):** Bone resorption is increased in young adults with thalassemia major. *British Journal of Hematology*, 112(1):35-41.
- Voskaridou E, Terpos E, Skorchili, M. , et al. (2004)** New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia. *Br J Haematol*; 127:127-139.
- Weatherall, D.J. (1999):** Genetic disorders of haemoglobin. In: Hoffbrand A.V., Lewis S.M. and Tuddenham, E.G.D. (eds) *Postgraduate haematology*, 4th ed . Butterwerth Heinemann, Ch. 6, P. 91-118.
- Weatherall, D.J. and Clegg, J.B. (1996):** Thalassemia a global public health problem. *Nat. Med.*, 2: 847-849.
- Weatherall, D.J. and Clegg, J.B. (2001):** The thalassemia syndromes. Oxford: Blackwell science 724-729.
- Weatherall, D.J. (2001):** The thalassemias. In: *The molecular basis of blood diseases*. Stamatuyannopoulos G, Nienhuis AW, Majerus PH, Varmus H, eds. 3rd ed. Philadelphia: WB Saunders, 183-220.

Weinstein DA, Roy CN, Fleming MD, Loda MF, et al., (2002):

Inappropriate expression of hepcidin is associated with iron refractory anemia: Implications for the anemia of chronic disease. *Blood*; 100(10):3776-81.

Wheeler MH and Lasuraz JH (1994): Diseases of the Thyroid, London,

Galasco, Wheinheim, New York, Tokyo, Melbourne, Madras: Chapman and Hall medical; 109-115.

Yaish, H.M. (2001): Thalassemia at www.emedicine.com.

Zervas A, Katopodi A, Loda MF, et al., (2002) Assement of thyroid

functions in 200 patients with thalassemia major. *Thyroid* vol.12 number (2) p.151- 154

Zurakowski D, Di Canzio J and Majzoub JA. (1999) Pediatric

reference intervals for serum thyroxine, triiodo thyronine, thyrotropin, and free thyroxine. *Clin Chem*; 45:1087–109